

Health, Building 45, Bethesda, MD 20892, (301) 594-8886.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group Diabetes, Endocrinology and Metabolic Diseases B Subcommittee.

*Date:* June 9, 2000.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Ramada, Inn., 8400

Wisconsin Ave, Bethesda, MD 20814.

*Contact Person:* Ned Feder, MD, Scientific Review Administrator, Review Branch, DEA, NIDDK, Room 645, 6707 Democracy Boulevard, National Institutes of Health, Bethesda, MD 20892.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group, Digestive Diseases and Nutrition C Subcommittee.

*Date:* June 13-14, 2000.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn—Bethesda, 8120

Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Dan Matsumoto, PhD, Scientific Review Administrator, Review Branch, DEA, NIDDK, Room 649, 6707 Democracy Boulevard, National Institutes of Health, Bethesda, MD 20892-6600, (301) 594-8894.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: May 12, 2000.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 00-12904 Filed 5-22-00; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Cell Development and Function Integrated Review Group, Cell Development and Function 2.

*Date:* June 1-2, 2000.

*Time:* 8 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Chevy Chase Holiday Inn, 5520 Wisconsin Ave., Chevy Chase, MD 20815.

*Contact Person:* Ramesh K. Nayak, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5146, MSC 7840, Bethesda, MD 20892, (301) 435-1026.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Molecular, Cellular and Developmental Neuroscience Integrated Review Group Visual Sciences C Study Section.

*Date:* June 1-2, 2000.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Doyle Washington Hotel, 1500 New Hampshire Ave., NW, Washington, DC 20036.

*Contact Person:* Carole L. Jelsema, PhD, Chief, MDCN Scientific Review Group, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5210, MSC 7850, Bethesda, MD 20892, (301) 435-1249, jelsemac@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* June 4-6, 2000.

*Time:* 7 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Sheraton Chapel Hill, One Europa Drive, Chapel Hill, NC 27514.

*Contact Person:* Lee Rosen, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5116, MSC 7854, Bethesda, MD 20892, (301) 435-1171.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* June 5, 2000.

*Time:* 8 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Georgetown Suites Hotel-Harbor Building, 1000 29th Street NW, Washington, DC 20007.

*Contact Person:* Eugene Vigil, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5144, MSC 7840, Bethesda, MD 20892, (301) 435-1025.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel SSS-K 02 S.

*Date:* June 5, 2000.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* River Inn, 924 25th Street, NW, Washington, DC 20037.

*Contact Person:* Lawrence N. Yager, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4200, MSC 7808, Bethesda, MD 20892, 301-435-0903, yagerl@csr.nih.gov

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* June 6-7, 2000.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Clarion Hampshire Hotel, 1310 New Hampshire Ave, NW, Washington, DC 20036.

*Contact Person:* Jay Joshi, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5184, MSC 7846, Bethesda, MD 20892, (301) 435-1184.

*Name of Committee:* Cardiovascular Sciences Integrated Review Group Pathology A Study Section.

*Date:* June 6-7, 2000.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Wyndham City Center, 1143 New Hampshire Avenue NW, Washington, DC 20037.

*Contact Person:* Larry Pinkus, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4132, MSC 7802, Bethesda, MD 20892, (301) 435-1214.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: May 16, 2000.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 00-12890 Filed 5-22-00; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Public Health Service

#### Meeting: National Toxicology Program; Center for Evaluation of Risks to Human Reproduction

National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS), Center for the Evaluation of Risks to Human Reproduction, announces an Expert Panel Meeting to complete a review of seven phthalates. The review will take

place on July 12–13, 2000, at the Sheraton National Hotel 900 S. Orme Street (Columbia Pike and Washington Boulevard) Arlington, VA 22204. The meeting is open to the public and attendance is limited only by the availability of space.

### Background

The NTP and the NIEHS established the NTP Center for the Evaluation of Risks to Human Reproduction (CERHR) [Federal Register (FR), December 14, 1998 (Volume 63, Number 239, page 68782)] in June 1998. The purpose of the Center is to provide timely and unbiased, scientifically sound evaluations of human and experimental evidence for adverse effects on reproduction, including development, which may be caused by agents to which humans are exposed. An expert panel is established to review the scientific evidence on the chemical(s) under review, receive public comments, and then prepare a report on the chemical(s) that is publicly available and is also published in Environmental Health Perspectives (EHP). NTP staff prepares a final NTP Center Report on the evaluated chemical(s) that integrates background information on the chemical(s), findings of the expert panel, a summary of public comments, and a discussion of any additional, recent studies. The final report is made publicly available, distributed to interested stakeholders, appropriate regulatory and research agencies, and published in EHP. A summary of the complete review process can be found on the CERHR website (<http://cerhr.niehs.nih.gov>), in FR March 20, 2000 (Volume 65, Number 54, page 14497), or a hardcopy may be requested from Ms. Sheren (see below).

The Center is completing a review of the following seven phthalate esters (Chemical Abstracts Service registry numbers are in parentheses):

butyl benzyl phthalate (85–68–7) BBP  
di(2-ethylhexyl) phthalate (117–81–7) DEHP

di-isodecyl phthalate (26761–40–0, 68515–49–1) DIDP

di-isononyl phthalate (28553–12–0, 68515–48–0) DINP

di-n-butyl phthalate (84–74–2) DBP  
di-n-hexyl phthalate (84–75–3) DnHP  
di-n-octyl phthalate (117–84–0) DnOP

An independent, expert panel began the phthalate review at the first Phthalate Expert Panel Meeting on August 17–19, 1999, in Alexandria, VA [FR August 5, 1999 (Volume 64 Number 150, pp. 42707–42708)]. Prior to this meeting, panelists reviewed existing literature in their areas of expertise and

provided other panel members with their summary evaluations. This effort involved the review of nearly 1,000 reports or publications covering general toxicity in animals and humans, developmental and reproductive toxicity, and information on human exposure. The Expert Panel continued its work at a second meeting held on December 15–17 in Research Triangle Park, NC [FR November 19, 1999 (Volume 64 Number 223, pp. 63327–63329)]. Summaries of the first two Phthalate Expert Panel meetings are available on the Center's website (<http://cerhr.niehs.nih.gov>) or can be obtained in hardcopy from Ms. Sheren (see below).

### Review Panel

A panel of 16 independent scientists selected for their expertise in various aspects of reproductive toxicology and other relevant areas are conducting this review. The roster of experts follows:

#### PHthalates EXPERT PANEL

Name	Affiliation
Kim Boekelheide, MD, PhD.*	Brown University, Providence, RI
Bob Chapin, PhD .....	NIEHS, Research Triangle Park, NC
Mike Cunningham, PhD.*	NIEHS, Research Triangle Park, NC
Elaine Faustman, PhD.	University of Washington, Seattle, WA
Paul Foster, PhD .....	Chemical Industry Institute of Toxicology, Research Triangle Park, NC
Mari Golub, PhD .....	Cal/EPA, Davis, CA
Rogene Henderson, PhD.	Inhalation Toxicology Research Institute, Albuquerque, NM
Irwin Hinberg, PhD ....	Health Canada, Ottawa, Ontario, Canada
Bob Kavlock, PhD (chair).	EPA/ORD, Research Triangle Park, NC
Ruth Little, Sc.D .....	NIEHS, Research Triangle Park, NC
Jennifer Seed, PhD ...	EPA/OPPT, Washington, DC
Katherine Shea, MD	North Carolina State University, Raleigh, NC
Sonia Tabacova, MD, PhD.	FDA, Rockville, MD
Shelley Tyl, PhD .....	Research Triangle Institute, Research Triangle Park, NC
Paige Williams, PhD	Harvard University, Cambridge, MA
Tim Zacharewski, PhD.	Michigan State University, East Lansing, MI

\* Unable to attend the Final Phthalate Expert Panel meeting.

### Preliminary Agenda

The Expert Panel's primary activities at the third and final meeting will be to: (1) Review and approve Integrated Evaluation (Section 5.2) language of the five reports (DnHP, DnOP, DINP, DIDP, and DBP) proposed at the December meeting and generally agreed through review and comment following that meeting and (2) review and discuss Data Summary and Integration (Section 5) of the reports for two phthalates, BBP and DEHP. Initial discussion will be in plenary sessions. All aspects of BBP will be discussed, whereas, the main focus of the DEHP discussion will be data relevant to use of medical products that contain this phthalate. It is expected that the Expert Panel will approve Section 5 language for DEHP and BBP before the end of the July meeting.

#### Wednesday, July 12, 2000

8:30 am—Introductory Remarks and Status of Phthalate Review  
9:00 am—Phthalates Expert Panel Opening Comments

Review of BBP (Section 5.0, including 5.1–5.3)

9:10–9:30 am—Public Comments on BBP

9:30–9:40 am—Break  
9:40–12 N—Panel Review of BBP  
12N–1:00 pm—Lunch

1:00–2:45 pm—Summaries of Previously Reviewed Phthalate Reports, DnHP, DnOP, DINP, DIDP, DBP (Section 5.2 of each report) Public Comment

Expert Panel Discussion and Approval of Sections 5.2

2:45–3:00 pm—Break

Review of DEHP (Section 5.0, including 5.1–5.3)

3:00–3:15 pm—Public Comments on DEHP

3:15–4:30 pm—Panel Review of DEHP  
4:30–6:00 pm—Panelists Work on Plenary Assignments

6:00 pm—Progress Report on Plenary Assignments

6:30 pm—Adjourn

#### Thursday, July 13, 2000

8:30–10:00 am—Panel Review of Revised BBP Report

10:00–10:15 am—Break

10:15–11:00 am—Panel Review of Revised DEHP Report

11:00–1:00 pm—Panel Works on Plenary Assignments (working lunch)

1:00–2:30 pm—Expert Panel Discussion and Approval of BBP Report

2:30–2:45 pm—Break

2:45–4:15 pm—Expert Panel Discussion and Approval of DEHP Report

4:15–4:45 pm—Public Comments  
 4:45–5:00 pm—Closing Remarks  
 5:00 pm—Adjourn

#### Abbreviations:

BBP—butyl benzyl phthalate (85–68–7)  
 DEHP—di(2-ethylhexyl) phthalate (117–81–7)  
 DIDP—di-isodecyl phthalate (26761–40–0, 68515–49–1)  
 DINP—di-isononyl phthalate (28553–12–0, 68515–48–0)  
 DBP—di-n-butyl phthalate (84–74–2)  
 DnHP—di-n-hexyl phthalate (84–75–3)  
 DnOP—di-n-octyl phthalate (117–84–0)

#### Reports Available for Public Review

Based on deliberations at the previous meetings. Expert Panel Reports are currently being finalized. Each Report is composed of the following sections:

- 1.0 Exposure
- 2.0 General Toxicological and Biological Parameters
- 3.0 Developmental Toxicity Data
- 4.0 Reproductive Toxicity Data
- 5.0 Data Summary & Integration
- 5.1 Summary (Sections 1–4)
- 5.2 Integrated Evaluation
- 5.3 Critical Data Needs

All sections of the reports for DIDP, DINP, DnHP and DnOP will be available to the public after May 15 and for DBP, BBP and DEHP after June 1. They can be obtained electronically on the CERHR website (<http://cerhr.niehs.nih.gov>) or in hardcopy by contacting Ms. Sheren at the address given below.

#### Solicitation of Public Comments

As shown on the above preliminary agenda, time is allotted at this meeting for public comments (seven minutes per speaker). It is expected that comments will be directed to the specific portions of the reports being discussed by the Expert Panel. In order to facilitate

planning of this meeting, those wishing to make public comments are asked to submit their comments in writing, provide an electronic copy, and notify Ms. Sheren, (see below) no later than June 30, 2000. Please reference the specific draft phthalate report the comments address. Provide your name, affiliation, mailing address, phone, fax, e-mail and sponsoring organization (if any) and send a copy of the statement or talking points to Ms. Sheren. This information will be provided to the Panel and will assist the Chair and Panel Members in identifying issues for discussion. Registration for public comments will also be available on-site (7:30–8:30 a.m.). Those registering on site are asked to bring 40 copies of their statement or talking points.

A written statement may be submitted in lieu of making an oral presentation. These written comments should be received by Ms. Sheren no later than June 30 in order for them to be considered at the July 12–13 meeting. Persons sending written comments are asked to provide their name, affiliation, mailing address, phone, fax, e-mail and sponsoring organization (if any) and provide an electronic copy. Please reference the specific draft phthalate report the comments address.

Following this meeting, there will be another opportunity for written comment on each Expert Panel Report. These public comments will be considered in the final NTP Center Report prepared by the NTP staff and subsequently distributed to Federal and State Agencies, interested stakeholders and the public.

An index of written public comments will be posted on the CERHR website (<http://cerhr.niehs.nih.gov>). This index and copies of specific public comments may be obtained by contacting Ms. Sheren.

For other questions or additional information about the meeting, please contact Ms. Peggy Sheren at CERHR, 1800 Diagonal Road, Suite 500, Alexandria, VA 22314–2808, Phone: (703) 838–9440, [psheren@sciences.com](mailto:psheren@sciences.com).

Dated: May 12, 2000.

**Samuel H. Wilson,**

*Deputy Director, National Institute of Environmental Health Sciences.*

[FR Doc. 00–12908 Filed 5–22–00; 8:45 am]

BILLING CODE 4140–01–U

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Fiscal Year (FY) 2000 Funding Opportunities

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice of Funding Availability.

**SUMMARY:** The Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Treatment (CSAT) announces the availability of FY 2000 funds for grants for the following activity. This activity is discussed in more detail under section 3 of this notice. This notice is not a complete description of the activity; potential applicants *must* obtain a copy of the Program Announcement, including Part I, Programmatic Guidance for Grants to Expand Substance Abuse Treatment Capacity in Targeted Areas of Need, and Part II, General Policies and Procedures Applicable to all SAMHSA Applications for Discretionary Grants and Cooperative Agreements, before preparing an application.

Activity	Application deadline	Est. funds FY 2000	Est. No. of awards	Project period
HIV Services Integration Planning Grants.	July 28, 2000 .....	up to \$3.5 million .....	25–30 .....	1 year

The actual amount available for awards and their allocation may vary, depending on unanticipated program requirements and the number and quality of applications received. FY 2000 funds for the activity discussed in this announcement were appropriated by the Congress under Public Law 106–113. SAMHSA's policies and procedures for peer review and Advisory Council review of grant and cooperative agreement applications were published in the **Federal Register** (Vol. 58, No. 126) on July 2, 1993.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. The SAMHSA Centers' substance abuse and mental health services activities address issues related to Healthy People 2000 objectives of Mental Health and Mental Disorders; Alcohol and Other Drugs; Clinical Preventive Services; HIV Infection; and Surveillance and Data Systems. Potential applicants may obtain a copy

of Healthy People 2000 (Full Report: Stock No. 017–001–00474–0) or Summary Report: Stock No. 017–001–00473–1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325 (Telephone: 202–512–1800).

SAMHSA will publish additional notices of available funding opportunities for FY 2000 in subsequent issues of the **Federal Register**.

**General Instructions:** Applicants must use application form PHS 5161–1 (Rev. 6/99; OMB No. 0920–0428). The